Blockchain Registration Transaction Record

VERAXA Expands Human-Relevant Testing for Cancer Pipeline

VERAXA Biotech (NASDAQ: VRXA) implements FDA-aligned New Approach Methodologies to advance its BiTAC T-cell engagers and antibody-drug conjugates for cancer, reducing animal testing.

The adoption of NAMs by VERAXA could accelerate the development of safer and more effective cancer therapies by improving the predictive power of preclinical studies. By reducing animal use and focusing on human-relevant models, the company may bring novel T-cell engagers and antibody-drug conjugates to patients faster, while also addressing ethical concerns and potentially lowering development costs. This approach aligns with regulatory trends and could set a precedent for other biotech firms, ultimately benefiting patients through more targeted and efficient drug development.